A. B. Mallick

发表

Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin

A. Negassa, J. Mariadason, A. Sood, 2019, Oncotarget.

Metabolic Pathways and Targets in Chondrosarcoma

U. Martinez-outschoorn, A. B. Mallick, I. Micaily, 2021, Frontiers in Oncology.

Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis

A. B. Mallick, Kamil M. Amer, J. Abraham, 2020, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.